Marstacimab for treating haemophilia A and B with inhibitors

Marstacimab is in clinical development for the treatment of haemophilia A haemophilia B with inhibitors in adults and adolescents. Haemophilia is a rare, inherited condition that slows blood clotting. There are two main types of haemophilia: haemophilia A (a deficiency in clotting factor VIII) and haemophilia B (a deficiency in clotting factor IX). Haemophilia is categorised as mild, moderate, and severe, based on the percentage of available clotting factors in the blood. Severe haemophilia can result in spontaneous bleeding of nose, gums, joints, and muscles. Without treatment people with severe haemophilia can develop joint deformities, soft tissue bleeding and serious internal bleeding. Some people with haemophilia can form an immune response to current treatment options therefore alternative treatment options are needed.